In a nutshell This study evaluated the outcomes of prostate cancer patients with persistently detectable levels of prostate-specific antigen (PSA) following radical prostatectomy (RP). Some background Radical prostatectomy or RP (surgical removal of the prostate gland and some tissue around it) is a common treatment for patients with prostate...
Read More
In a nutshell In the past several years, the treatment of prostate cancer has made significant progress. In this study, researchers reviewed recent studies evaluating treatments for patients with prostate cancer. Some background Prostate cancer progression is usually measured by blood levels of a protein called prostate-specific antigen (PSA) in a...
Read More
In a nutshell This study compared the effect of two chemotherapy drugs used in the treatment of metastatic prostate cancer. Survival rates and pain relief were compared with cabazitaxel (jevtana) or mitoxantrone (novantrone) therapy. Some background Testosterone, the main male sex hormone, facilitates in the growth of...
Read MoreIn a nutshell This phase 3 trial aims to determine if androgen suppression along with high dose proton radiation therapy offers more benefit than proton radiation therapy alone. The main outcome investigated is freedom from treatment failure. The details Freedom from treatment failure represents successful treatment with no local cancer...
Read MoreIn a nutshell This clinical trial evaluated the quality of life of men with locally advanced prostate cancer (PCa) treated with Leuprorelin and radiotherapy, with or without Zolendronic Acid (ZA). Quality of life measures improved with shorter duration of Leuprorelin treatment, regardless of combining ZA. Some background Prostate cancer...
Read More
In a nutshell This article reports the results of recent studies involving the drug Docetaxel (Taxotere). The drug did not improve overall survival when added to androgen-deprivation therapy. Smaller doses given in shorter treatment cycles were found to be easier to tolerate and more effective. Some background Prostate cancer grows in...
Read More
The present clinical trial evaluated the safety of an immune-based therapy (termed ‘combined immunotherapy’) as an alternative to chemotherapy for the treatment of metastatic (spread with distant metastases) prostate cancer non-responsive to hormonal treatment, or ‘castration-resistant prostate cancer’ (mCRPC). The trial aimed...
Read MoreIn a nutshell This study evaluated the safety of two regimens of external beam radiation – short, high-dose radiotherapy – compared with the standard radiotherapy protocol. There were no substantial differences in side effects between the conventional and experimental radiotherapy regimens. Some background Prostate cancer which...
Read More
In a nutshell The present study examined the duration of urinary-related side effects resulting from radiation therapy. Mild to severe urinary side effects were found to last up to 10 years post radiation therapy. Some background Prostate cancer is a slow growing form of cancer that is often managed by active surveillance or observation (delayed...
Read More
The aim of this article was to describe some of the most interesting developments concerning new therapies for advanced prostate cancer. During the last years new experimental therapeutic agents for the treatment of advanced prostate cancer have been developed. These are based on the recent discoveries on prostate cell function, resistance to...
Read More
